**Supplemental** table 3**: Descriptive values of figure 3. A)** Mean fluorescence intensity of adhesion molecules CD44 and CD31 on neutrophils of wild-type and adenosine A2B receptor -/- animals in circulation were evaluated after zymosan stimulation and after zymosan administration and sevoflurane treatment. **B)** CD162, CD54, CD44, and CD31 MFI were determined on neutrophils at indicated conditions. **C)** Expression of CD162, CD54, CD44, CD31, CD11a, and CD11b were detected on neutrophils in liver tissue of wild-type and adenosine A2B receptor -/- mice at indicated conditions. **D)** Mean fluorescence intensity of CD11b and CD11a on neutrophils in lung tissue of wild-type and adenosine A2B receptor -/- animals were evaluated after zymosan stimulation and after zymosan administration and sevoflurane treatment. All statistic data presented as the mean ± SD or as the median and 25%/75% percentile. Statistical analyses were performed by one-way ANOVA + Bonferroni test and two-group analyses by unpaired *t*-tests or Mann-Whitney tests.

|  |  |  |
| --- | --- | --- |
| **Table 3A Blood**  | **mean fluorescence intensity** | ***P* values; n counts** |
| CD44: wild-type with zymosanvs. wild-type with zymosan and sevoflurane | mean ± SD: 1.2 ± 0.4vs. 0.7 ± 0.2 | P<0.001n=8/11 |
| CD44: adenosine A2B receptor-/- with zymosanvs. adenosine A2B receptor-/- with zymosan and sevoflurane | mean ± SD 1.0 ± 0.3vs. 0.9 ± 0.2 | P=nsn=8/9 |
| CD31: wild-type with zymosanvs. wild-type with zymosan and sevoflurane | mean ± SD 1.0 ± 0.1vs. 0.8 ± 0.1 | P=0.003n=10/8 |
| CD31: adenosine A2B receptor -/- with zymosanvs. adenosine A2B receptor -/- with zymosan and sevoflurane | mean ± SD 1.0 ± 0.2vs. 1.0 ± 0.2 | P=nsn=9/8 |

|  |  |  |
| --- | --- | --- |
| **Table 3B Lavage**  | **mean fluorescence intensity** | ***P* values; n counts** |
| CD162: wild-type with zymosanvs. wild-type with zymosan and sevoflurane | median [25%,75%]: 110 [93, 123] vs. 74 [65, 89] | P=0.007n=9/9 |
| CD162: adenosine A2B receptor -/- with zymosanvs. adenosine A2B receptor -/- with zymosan and sevoflurane | median [25%,75%]: 111 [91, 132] vs. 126 [104, 155] | P=nsn=8/7 |
| CD54: wild-type with zymosanvs. wild-type with zymosan and sevoflurane | mean ± SD: 1.0 ± 0.1vs. 0.8 ± 0.1 | P=0.001n=8/7 |
| CD54: adenosine A2B receptor -/- with zymosanvs. adenosine A2B receptor -/- with zymosan and sevoflurane | mean ± SD: 1.00 ± 0.1vs. 0.9 ± 0.1 | P=nsn=8/8 |
| CD44: wild-type with zymosanvs. wild-type with zymosan and sevoflurane | mean ± SD: 1.1 ± 0.1vs. 0.8 ± 0.1 | P=0.001n=8/10 |
| CD44: adenosine A2B receptor -/- with zymosanvs. adenosine A2B receptor -/- with zymosan and sevoflurane | mean ± SD: 1.0 ± 0.2vs. 1.1± 0.2 | P=nsn=8/8 |
| CD31: wild-type with zymosanvs. wild-type with zymosan and sevoflurane | mean ± SD: 1.1 ± 0.2vs. 0.8 ± 0.1 | P=0.033n=9/8 |
| CD31: adenosine A2B receptor -/- with zymosanvs. adenosine A2B receptor -/- with zymosan and sevoflurane | mean ± SD: 1.0 ± 0.2vs. 0.9 ± 0.2 | P=nsn=8/8 |

|  |  |  |
| --- | --- | --- |
| **Table 3C Liver**  | **mean fluorescence intensity** | ***P* values; n counts** |
| CD162: wild-type with zymosanvs. wild-type with zymosan and sevoflurane | median [25%,75%]: 130 [117, 149] vs. 94 [82, 99] | P=0.006n=8/8 |
| CD162: adenosine A2B receptor -/- with zymosanvs. adenosine A2B receptor -/- with zymosan and sevoflurane | median [25%,75%]: 154 [141, 162] vs. 215 [193, 261] | P=0.001n=8/7 |
| CD54: wild-type with zymosanvs. wild-type with zymosan and sevoflurane | mean ± SD: 1.0 ± 0.1vs. 0.8 ± 0.1 | P=0.003n=8/8 |
| CD54: adenosine A2B receptor -/- with zymosanvs. adenosine A2B receptor -/- with zymosan and sevoflurane | mean ± SD: 1.0 ± 0.1vs. 0.9 ± 0.2 | P=nsn=7/7 |
| CD44: wild-type with zymosanvs. wild-type with zymosan and sevoflurane | mean ± SD: 1.1 ± 0.1 vs. 0.8 ± 0.1 | P=0.041n=8/8 |
| CD44: adenosine A2B receptor -/- with zymosanvs. adenosine A2B receptor -/- with zymosan and sevoflurane | mean ± SD: 1.0 ± 0.3vs. 1.5 ± 0.2 | P=nsn=8/7 |
| CD31: wild-type with zymosanvs. wild-type with zymosan and sevoflurane | mean ± SD: 1.1 ± 0.1vs. 0.9 ± 0.1 | P=0.039n=9/8 |
| CD31: adenosine A2B receptor -/- with zymosanvs. adenosine A2B receptor -/- with zymosan and sevoflurane | mean ± SD: 1.0 ± 0.2vs. 0.9 ± 0.2 | P=nsn=8/8 |
| CD11a: wild-type with zymosanvs. WT with zymosan and sevoflurane | mean ± SD: 277 ± 40vs. 199 ± 43 | P<0.001n=9/8 |
| CD11a: adenosine A2B receptor -/- with zymosanvs. adenosine A2B receptor -/- with zymosan and sevoflurane | mean ± SD: 270 ± 9vs. 311 ± 35 | P=0.047n=8/8 |
| CD11b: wild-type with zymosanvs. wild-type with zymosan and sevoflurane | mean ± SD: 4347 ± 414vs. 3589 ± 268 | P=0.013n=8/8 |
| CD11b: adenosine A2B receptor -/- with zymosanvs. adenosine A2B receptor -/- with zymosan and sevoflurane | mean ± SD: 4659 ± 578vs. 4577 ± 717 | P=nsn=8/7 |

|  |  |  |
| --- | --- | --- |
| **Table 3D Lung** | **mean fluorescence intensity** | ***P* values; n counts** |
| CD11b: wild-type with zymosanvs. wild-type with zymosan and sevoflurane | mean ± SD: 3173 ± 400vs. 2451 ± 210 | P=0.001n=8/8 |
| CD11b: adenosine A2B receptor -/- with zymosanvs. adenosine A2B receptor -/- with zymosan and sevoflurane | mean ± SD: 2993 ± 359vs. 2842 ± 383 | P=nsn=8/7 |
| CD11a: wild-type with zymosanvs. wild-type with zymosan and sevoflurane | mean ± SD: 267 ± 31vs. 3589 ± 267 | P=0.009n=8/8 |
| CD11a: adenosine A2B receptor -/- with zymosanvs. adenosine A2B receptor -/- with zymosan and sevoflurane | mean ± SD: 236 ± 38vs. 257 ± 16 | P=nsn=8/8 |